Affimed NV
NASDAQ:AFMD
Intrinsic Value
Affimed NV engages in the discovery and development of cancer immunotherapies. [ Read More ]
The intrinsic value of one AFMD stock under the Base Case scenario is 8.28 USD. Compared to the current market price of 5.15 USD, Affimed NV is Undervalued by 38%.
Valuation Backtest
Affimed NV
Run backtest to discover the historical profit from buying and selling AFMD stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Affimed NV
Current Assets | 84.2m |
Cash & Short-Term Investments | 72m |
Receivables | 5.3m |
Other Current Assets | 6.8m |
Non-Current Assets | 13m |
PP&E | 12.9m |
Intangibles | 25k |
Current Liabilities | 25.9m |
Accounts Payable | 18.9m |
Other Current Liabilities | 7m |
Non-Current Liabilities | 13.4m |
Long-Term Debt | 13m |
Other Non-Current Liabilities | 464k |
Earnings Waterfall
Affimed NV
Revenue
|
8.3m
EUR
|
Cost of Revenue
|
-1.3m
EUR
|
Gross Profit
|
6.9m
EUR
|
Operating Expenses
|
-114.5m
EUR
|
Operating Income
|
-107.6m
EUR
|
Other Expenses
|
1.7m
EUR
|
Net Income
|
-105.9m
EUR
|
Free Cash Flow Analysis
Affimed NV
AFMD Profitability Score
Profitability Due Diligence
Affimed NV's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Affimed NV's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
AFMD Solvency Score
Solvency Due Diligence
Affimed NV's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Affimed NV's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AFMD Price Targets Summary
Affimed NV
According to Wall Street analysts, the average 1-year price target for AFMD is 23.31 USD with a low forecast of 5.05 USD and a high forecast of 63 USD.
Shareholder Return
AFMD Price
Affimed NV
Average Annual Return | 7.27% |
Standard Deviation of Annual Returns | 87.12% |
Max Drawdown | -97% |
Market Capitalization | 76.9m USD |
Shares Outstanding | 14 939 916 |
Percentage of Shares Shorted | 1.43% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Affimed NV engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 187 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Contact
IPO
Employees
Officers
The intrinsic value of one AFMD stock under the Base Case scenario is 8.28 USD.
Compared to the current market price of 5.15 USD, Affimed NV is Undervalued by 38%.